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Daptomycin-induced eosinophilic
pneumonia - a systematic review
Priyasha Uppal1, Kerry L. LaPlante1,2,3, Melissa M. Gaitanis1,3, Matthew D. Jankowich1,3 and Kristina E. Ward2*
Abstract
Purpose: Eosinophilic pneumonia comprises a group of lung diseases in which eosinophils appear in increased
numbers in the lungs and sometimes in the bloodstream. Several case reports link daptomycin use to this
phenomenon.
Summary: We performed a systematic literature review to identify cases of eosinophilic pneumonia associated with
daptomycin use. Relevant studies were identified by searching Pubmed/Medline, EMBASE, Google Scholar, Cochrane
Database of Systematic Reviews, and Clin-Alert from inception to May 2016, and manual searches of reference lists. All
case reports that include information regarding patient age, indication, clinical and objective findings, treatment and
outcome were evaluated. Abstracts from conference proceedings as well as case reports not in English were excluded.
Descriptive statistics were used to analyze the data. Thirty-five patient-cases were included in the final analysis. Patients
most likely to be identified with daptomycin-induced eosinophilic pneumonia were male (83%) and elderly (mean age
65.4 ± 15 years). The dose for daptomycin ranged from 4 to 10 mg/kg/day, but included a large number of patients
with renal dysfunction. The average duration of daptomycin therapy upon onset of EP symptoms was 2.8 ± 1.6 weeks.
Majority of patients presented with dyspnea (94%), fever (57%) and were also found to have peripheral eosinophilia
(77%) and infiltrates/opacities of CT/CXR (86%). Symptom improvement was seen after daptomycin discontinuation
(24 h to 1 week). The majority of patients were also prescribed treatment with corticosteroids (66%).
Conclusion: Clinicians should be aware of daptomycin-induced eosinophilic pneumonia and its symptoms along with
its presentation and treatment.
Keywords: Daptomycin, Eosinophilia, Pneumonia
Background
Eosinophilic pneumonia is a rare, but serious respiratory
syndrome that occurs when eosinophils accumulate in the
lungs [1, 2]. It has been associated with several medica-
tions and chemicals, with antibiotics and nonsteroidal
anti-inflammatory drugs among the most common [3, 4].
The pathophysiology of acute eosinophilic pneumonia is
thought to be caused by detection of an antigen by alveo-
lar macrophages which leads to recruitment of T-helper 2
lymphocytes and subsequent release of interleukin 5.
Interleukin 5 promotes eosinophil production and migra-
tion to the lung. Additionally, eotaxin (a potent eosinophil
chemoattractant) production by alveolar macrophages,
pulmonary endothelial cells, airway smooth muscle cells,
and alveolar epithelial cells leads to further accumulation
of eosinophils in the lungs [5].
Daptomycin is a cyclic lipopeptide antibiotic derived from
the fermentation of Streptomyces roseosporus. Daptomycin
has activity against Gram-positive organisms including
methicillin-resistant Staphylococcus aureus (MRSA) and
vancomycin-resistant enterococci (VRE) [6]. In 2007,
pulmonary eosinophilia was added to the “Adverse Reac-
tions, Post-Marketing Experience” section of the product
label for daptomycin [2]. A review of the literature and the
US FDA Adverse Event Reporting System database in 2012
revealed 7 definite, 13 probable, and 38 possible cases of
daptomycin-induced eosinophilic pneumonia [1]. While
the mechanism of daptomycin’s pulmonary toxicity is not
known, the drug undergoes conformational change through
interaction with calcium which allows binding to the cyto-
plasmic membrane, increased membrane permeability, and
intracellular ion escape [7]. The antibacterial activity of
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daptomycin is decreased because of its binding to pulmon-
ary surfactant. Some have speculated two potential mecha-
nisms for daptomycin’s pulmonary toxicity: 1) chronic
daptomycin administration results in drug accumulation
near the epithelial alveolar surface causing epithelial injury
and pneumonia and 2) the daptomycin-surfactant inter-
action could alter lipid integrity which may stimulate an in-
flammatory response [3, 7, 8].
Per the FDA guidance, eosinophilic pneumonia is attrib-
uted to daptomycin when the following criteria are met:
1) concurrent exposure to daptomycin, 2) fever, 3) dys-
pnea with increased oxygen requirement or requiring
mechanical ventilation, 4) new infiltrates on chest x-ray or
computed tomography (CT) scan, 5) bronchoalveolar lav-
age (BAL) with > 25% eosinophils, and 6) clinical improve-
ment following daptomycin withdrawal [2]. Solomon and
Schwartz [4] have also developed criteria for drug- or
toxin-induced eosinophilic pneumonia that is similar
and includes 1) presence of simple, acute, or chronic
eosinophilic pneumonia by diagnostic criteria which
includes excess of eosinophils either on lung biopsy
or BAL (usually ≥25%) in the setting of parenchymal
infiltrates 2) presence of a potential candidate drug or
toxin in an appropriate time frame 3) no other cause
of eosinophilic pneumonia such as fungal or parasitic
infection 4) clinical improvement after cessation of
the drug or toxin, and 5) recurrence of eosinophilic
pneumonia with re-challenge to the drug or toxin.
However, re-challenge is often not recommended as it
can be dangerous [4, 5].
Although the mechanism of daptomycin-induced eosino-
philic pneumonia is unknown, some have speculated that
daptomycin may bind to human surfactant and accumulate
in the alveolar space causing injury to the epithelium with
resulting inflammation [7, 8]. The purpose of this review is
to systematically evaluate the published literature describing
daptomycin-induced eosinophilic pneumonia.
Methods
All relevant cases and studies were identified by systematic-
ally searching of the PubMed, EMBASE, Google Scholar,
Cochrane Database of Systematic Reviews, and Clin-Alert
databases by two reviewers from inception through May
2016. The truncated terms “daptomycin”, “eosinophil*”, and
“pneumon*” were searched in each database. All case re-
ports that included information regarding patient age, indi-
cation, clinical and objective findings, treatment, and
outcome were evaluated. Reports not published in English
were excluded as well as abstracts from conference pro-
ceedings. Descriptive analysis was used to present pooled
demographic information and other data where applicable.
Results
No clinical or observational trials assess daptomycin-
induced eosinophilic pneumonia; only case reports and case
series are published. In 2012, Kim et al. identified 7 definite,
13 probable, and 38 possible cases of daptomycin-induced
eosinophilic pneumonia via review of literature and FDA
Adverse Event Reporting System Reports (AERS) as defined
in Table 1 [1]. Details regarding the 38 possible cases
reported through AERS were not described. Of the 20
cases that were identified as definite or probable, 9
have been published in the literature, the remaining
11 were summarized by Kim [1, 3, 9–13]. We also
identified 39 additional cases of eosinophilic pneumo-
nia attributed to daptomycin for a total of 59 cases
described in the literature [7, 14–24]. Of those, 21
were excluded from this systematic review because
they were abstract presentations at international
meetings and did not go through the peer review
publishing process [25–41]. Another three were ex-
cluded because they were not published in English
[42–44]. Currently available data on a total of 35
cases of daptomycin-induced eosinophilic pneumonia
is summarized in Table 2.
Table 1 Criteria for inclusion as definite, probably, possible, and unlikely cases of daptomycin-induced eosinophilic pneumonia [1, 2]
Definite Probable Possible Unlikely
Concurrent exposure to daptomycin Concurrent exposure to daptomycin Concurrent exposure to daptomycin All other cases that
did not meet criteria
Dyspnea with increased oxygen
requirement or requiring mechanical
ventilation
Dyspnea with increased oxygen
requirement or requiring mechanical
ventilation
New infiltrates on CXR or CT
New infiltrates on CXR or CT New infiltrates on chest x-ray or CT Clinical improvement following
daptomycin withdrawal OR the patient
died
BAL with > 25% eosinophils BAL with ≤ 25% eosinophils OR
peripheral eosinophilia
Clinical improvement following
daptomycin withdrawal
Clinical improvement following
daptomycin withdrawal
Fever
Adapted from references 1 and 2
Abbreviation: BAL bronchoalveolar lavage; CT computed tomography; CXR chest x-ray
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Table 2 Summary of 35 cases of presumed daptomycin-induced eosinophilic pneumonia
Case Age/
Sex
Indication Dose
(mg/kg/
day)
DAP
Duration
(wks)
Clinical Findings Objective Findings Treatment Outcome
Kim [1] (2012) 63/F MSSA spinal osteomyelitis 6 3 • Fever
• Cough,
hypoxemia
• BAL = 60–70%
• Peripheral eosinophilia
• Elevated CPK
• DAP d/c
• Corticosteroids
Recovered
64/
M
Osteomyelitis with
bacteremia
5.7 4 • Fever
• Dyspnea, hypoxia
• BAL = 44%
• Peripheral eosinophilia
• Pulmonary infiltrates
• DAP d/c Recovered
79/
M
Endocarditis 6 6 • Fever, cough,
night sweats
• Dyspnea
requiring MV
• BAL = 9–13%
• Peripheral eosinophilia
• CT = ground glass opacities
• Lung biopsy = eosinophilic
pneumonitis
• DAP d/c
• Corticosteroids
Improved
26/
M
MRSA bacteremia 7.35 1.4 • Dyspnea
requiring MV
• BAL not performed
• Peripheral eosinophilia
• Pulmonary infiltrates
• Eosinophils in tracheal aspirate
• DAP d/c Improved
43/
M
MRSA osteomyelitis 6 1–2 • Pleuritic pain
• Hypoxia requiring
O2
• BAL not performed
• Peripheral eosinophilia
• CT = bilateral infiltrates
• DAP d/c
• Given NSAIDs,
meperidine
• Improved
• Residual
infiltrates on
CT s/p 4 wks
66/
M
MSSA bacteremia 6 1 • Dyspnea
requiring O2
• Hematemesis
• BAL with eosinophils
(not quantified)
• Peripheral eosinophilia
• DAP d/c
• Corticosteroids
Recovered
71/
M
MRSA diabetic foot
infection
4 7.7 • Dyspnea
requiring O2
• Peripheral eosinophilia
• Elevated CRP
• Elevated ESR
• CT = bilateral interstitial opacities
• DAP d/c Improved
77/F Bacteremia (enterococcal) 5 1 • Dyspnea
requiring O2
• Peripheral eosinophilia
• CXR = pneumonitis
• DAP d/c
• Corticosteroids
Improved
67/
M
MRSA endocarditis 6 4.3 • Dyspnea
requiring MV
• BAL = 9%
• Peripheral eosinophilia
• CT = bilateral pulmonary
infiltrates
• DAP d/c
• Corticosteroids
Improved
73/
M
Prosthetic joint infection 5 3.7 • Fever
• Dyspnea
requiring MV
• Peripheral eosinophilia
• CT = bilateral ground glass
appearance
• DAP d/c
• Corticosteroids
Recovered
81/F MRSA paraspinal abscess 6 1.6 • Dyspnea
requiring MV
• BAL = 2% (s/p corticosteroid)a
• CXR = bilateral mid-lung infiltrates
• DAP d/c
• Corticosteroids
Improved
Cobb [6] (2007) 84/
M
Infection of left knee
prosthesis
4 4 • Decreased
appetite
• Weight loss
• Fatigue
• Weakness
• Elevated ESR
• CT with infiltrates
• Lung biopsy = eosinophilic
pneumonia
• DAP d/c • Improved within
2 weeks
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Table 2 Summary of 35 cases of presumed daptomycin-induced eosinophilic pneumonia (Continued)
Hayes [7] (2007) 60/
M
MSSA endocarditis NR 2 • Fever, rigors,
diaphoresis
• Required MV
• BAL 16% initially
• BAL 26% after rechallenge
• CRP elevated
• DAP d/c – then re-
challenged
• DAP d/c plus
corticosteroids
• Rechallenge failed
within 4 h
• Improved within 24 h
after DAP d/c
Kakish [8] (2008) 65/
M
MRSA vertebral osteomyelitis,
epidural abscess
6 2 • Low-grade fever
• Dyspnea
requiring MV
• BAL = 33%
• Peripheral eosinophilia
• Lung biopsy revealed eosinophils
• DAP d/c
• Corticosteroids
• Improved within 72 h
• Normal CT at
3 months
Shinde [9] (2009) 54/
M
Complicated inguinal hernia repair NR 2 • Low grade fever,
cough
• Hypoxemia
requiring MV
• Peripheral eosinophilia
• CT = bilateral airspace, peripheral
predominance, small bilateral effusions
• Lung biopsy =many eosinophils
• DAP d/c
• Corticosteroids
• Improved within 24 h
• Normal CT at 4 weeks
Lal [10] (2010) 82/
M
Prosthetic joint infection NR 3 • Fever
• Hypoxia requiring
O2
• BAL = 14%
• Peripheral eosinophilia
• CT = patchy bilateral infiltrates
• DAP d/c
• Corticosteroids
• Recovered after
5 days
• Recurrent symptoms
• Low dose steroids
required
87/
M
Prosthetic knee infection NR 4 • Dyspnea, dry
cough requiring
O2
• Malaise, chills,
anorexia, fever
• BAL = 40%
• Peripheral eosinophilia
• CT = bilateral patchy pulmonary
infiltrates
• DAP d/c
• Corticosteroids
• Recurrence s/p
steroid taper
• Low dose steroids for
2 years
Miller [11] (2010) 60/
M
MSSA prosthetic hip infection 6 2 • Cough, fever
• Hypoxia requiring
O2
• BAL = 81% after rechallenge
• Peripheral eosinophilia
• CT = bilateral scattered ground-glass
opacities
• Lung biopsy = acute fibrinous and
organizing pneumonia, reactive
alveolar and interstitial epithelial changes
• DAP d/c
• Rechallenged, DAP
d/c
• Corticosteroids
• Improved within 48 h
• Rechallenge failed
within 24 h
60/
M
MRSA osteomyelitis, septic arthritis 6 2 • Non-productive
cough, dyspnea
• Low-grade fevers,
chills
• Peripheral eosinophilia
• CT = patchy peripheral
nodular/ground-glass
• DAP d/c • Resolution within
96 h
• Recurrence with re-
challenge at 5 months
83/
M
Diskitis of lumbar spine 6 4 • Progressive
dyspnea,
• Cough, pleuritic
chest pain
• BAL = 13%
• Peripheral eosinophilia
• CT = diffuse ground-glass, reticular
opacities
• Lung biopsy = acute organizing
pneumonia, eosinophilia, chronic
inflammation, fibro-inflammatory
changes
• DAP d/c
• Corticosteroids
Improved within
6 days
Kalogeropoulous
[12] (2011)
78/
M
Endocarditis 8 1.4 • Fever, chills,
diaphoresis,
• Hypoxemia
requiring O2
• BAL = 27.5%
• Peripheral eosinophilia
• Elevated ESR
• Elevated CRP
• CT = patchy consolidation,
ground-glass opacities, bilateral
pleural effusions
• DAP d/c Resolution within 24 h
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Table 2 Summary of 35 cases of presumed daptomycin-induced eosinophilic pneumonia (Continued)
Rether [13]
(2011)
69/
M
Spondylo-discitis with lumbar
epidural and bilateral psoas
abscesses
6 3 • Fever
• Dyspnea
requiring O2
• BAL = 30%
• Elevated CRP
• CXR = extensive patchy infiltrates
in RLL and entire left lung
• DAP d/c
• Corticosteroids
Improved within 24 h
Patel [14] (2014) 61/F Osteomyelitis NR 1 • Dry cough
• Dyspnea
requiring MV
• BAL = 30%
• Peripheral eosinophilia
• CT = bilateral pleural effusion,
diffuse bilateral patchy infiltrate
• DAP d/c
• Corticosteroids
Improved within 72 h
Phillips [15] 2014) 48/
M
Osteomyelitis 6 3 • Fever
• Dyspnea
requiring MV
• BAL = 17%
• Peripheral eosinophilia
• CXR = patchy bilateral airspace
opacities
• DAP d/c
• Corticosteroids
• Improved
28/
M
Osteomyelitis 6 4 • Dyspnea
requiring MV
• Chest pain, light-
headedness
• BAL = 74%
• Peripheral eosinophilia
• CT = diffuse multi-lobar infiltrates
• DAP d/c
• Corticosteroids
Resolution within
1 week
Yamamoto [16]
(2014)
82/
M
MRSA bacteremia 10 2 • Low grade fever
• Hypoxia
• CT = bilateral ground glass opacities
• Sputum negative for eosinophils
• DAP d/c Improved
Yusuf [17] (2014) 64/
M
Prosthetic joint infection 10 4 • Fever • BAL = 47%
• Peripheral eosinophilia
• Elevated CRP
• CT = diffuse bilateral ground-glass
opacities
• DAP d/c Improved within 24 h
61/
M
Prosthetic joint infection 10 2 • Fever
• Dyspnea
requiring MV
• BAL = 3%
• Peripheral eosinophilia
• Elevated CRP
• CT = ground-glass consolidation,
bilateral pleural effusion
• DAP d/c Improved within 24 h
Chiu [18] (2015) 77/
M
Osteomyelitis 6 6 • Pleuritic chest
pain
• Cough, dyspnea
requiring O2
• BAL = 18%
• Elevated CRP
• CXR = diffuse bilateral airspace disease
• DAP was d/c 1 day
before symptoms
• Corticosteroids
Improved within 60 h
74/F Infected hip reconstruction 6 1b • Fever
• Dyspnea
requiring O2
• CXR – bilateral airspace disease • DAP d/c
• Corticosteroids
Improved within 24 h
Hagiya [19]
(2015)
34/
M
Endocarditis 10 1 • Cough with mild
hypoxemia
• Peripheral eosinophilia
• Elevated CRP
• CT = consolidation in peripheral
field of right upper lobe
• DAP d/c Resolved within
6 weeks
Hatipoglu [20]
(2015)
67/F MRSA diabetic foot ulcer NRc 3.3 • Cough, dyspnea
requiring BPAP
• Fever, fatigue,
decreased appetite
• Peripheral eosinophilia
• Elevated CRP
• CT = right lobe infiltration
• DAP d/c
• Inhaled
corticosteroids
Improved within 72 h
Roux [21] (2015) 67/
M
MSSA prosthetic hip
infection
6 2.4 • Dry cough,
hypoxemia
• BAL = 10%
• Peripheral eosinophilia
• DAP d/c
• Corticosteroids
Improved within 96 h
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Table 2 Summary of 35 cases of presumed daptomycin-induced eosinophilic pneumonia (Continued)
• CT = diffuse alveolar and
interstitial opacities
Wojtaszczyk [22]
(2015)
76/
M
Septic arthritis and
pacemaker vegetation
NR 2 • Dyspnea
requiring O2,
cough
• Fever, fatigue
• BAL = 58%
• Elevated CRP
• CT = bilateral ground glass
opacity, patchy consolidation
• DAP d/c
• Corticosteroids
Resolved within 72 h
Akcaer [23]
(2016)
60/
M
MSSA post-amputation
abscess
5 3.4 • Tachypnea,
hypoxia requiring
O2
• Peripheral eosinophilia
• Elevated CRP
• Elevated ESR
• HRCT = right pleural effusion,
bilateral tree-in-bud pattern,
bilateral scattered ground-glass
opacities
• DAP d/c Resolved within 72 h
KEY: BAL bronchoalveolar lavage, BPAP bilevel positive airway, CPK creatine phosphokinase, CRP C-reactive protein, CT computed tomography scan, CXR chest x-ray, DAP daptomycin, d/c discontinued, ESR erythrocyte
sedimentation rate, F female, HRCT high resolution computed tomography, M male, MRSA methicillin resistant Staphylococcus aureus, MSSA methicillin susceptible Staphylococcus aureus, MV mechanical ventilation, NR
not reported, NSAID nonsteroidal anti-inflammatory drug, O2 oxygen, RLL right lower lobe; s/p status post, wks weeks
a = DAP given for 1 week, then held for 2 weeks, and restarted. Symptom onset in 72 h after restarting, b = not included in analysis, c = DAP 500 mg/day given (dose mg/kg unknown)
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Analysis of the 35 cases shows eosinophilic pneumonia
resulting from daptomycin use is most likely to be re-
ported in males with a mean age of 65.4 ± 15 years and a
mean length of therapy of 2.8 ± 1.6 weeks at symptom
onset. The most common indication for daptomycin use
was osteomyelitis and/or diabetic foot infection closely
followed by prosthetic joint infection. Daptomycin dose
ranged from 4 to 10 mg/kg/day depending on renal
function; therefore, the adverse effect does not appear to
be dose dependent, but time dependent exposure. The
most common symptoms of eosinophilic pneumonia
included fever and dyspnea often requiring either oxygen
supplementation or mechanical ventilation. Other clinical
findings included malaise, elevated ESR (4/35 cases), or el-
evated C-reactive protein (11/35 cases). Peripheral eosino-
philia was also present in approximately 77% (27/35 cases)
of patients. Many cases also had computed tomography
scans or chest x-rays which revealed opacities (12/35
cases) and bilateral infiltrates (13/35 cases). Symptom
improvement was seen within 24 h through one week
after daptomycin discontinuation. The majority of patients
were also prescribed treatment with corticosteroids (23/35
cases); however, all patients were reported to recover
(See Table 3).
Discussion
While the criteria developed by Solomon and Schwartz
differ from the FDA guidance, they are largely similar in
that an offending agent (here, daptomycin) must be
present, >25% eosinophils are present, and that clinical
improvement is seen after discontinuation of the drug.
The FDA guidance also includes some measures of
symptomatology such as fever and dyspnea [2, 4].
Overall, dyspnea was the most common documented
symptom associated with eosinophilic pneumonia
followed by the presence of either pulmonary infiltrates
or opacities on chest x-ray or CT. A total of 10 cases
specifically mentioned the characteristic finding of
ground glass opacities on CT. A potential limitation of
this review is that some of the daptomycin-induced eo-
sinophilic pneumonia used lung biopsy in place of BAL
as part of the diagnostic criteria which is not part of the
FDA guidance, but is included in the Solomon and
Schwartz criteria. In addition, since some patients had
BAL < 25% eosinophils but lung biopsy revealed eosino-
philia [1, 13], a 25% cut off may be too strict in certain
situations.
Corticosteroids are believed to be beneficial at halting
clinical manifestations of daptomycin-induced eosino-
philic pneumonia and were used in the majority of re-
ported cases. Steroids exert action through eosinophilic
apoptosis and through accelerating intracellular signaling
involved in eosinophil death [45]. No dose or length of
corticosteroid treatment is established in guidelines for
eosinophilic pneumonia; however, a commonly employed
regimen is intravenous methylprednisolone 60–125 mg
every 6 h, with conversion to prednisone 40–60 mg oral
daily and taper over 2–6 weeks. Use of a 2- or 4-week
course appears to have similar time to resolution of clin-
ical symptoms and radiological abnormalities [46].
Conclusion
As use of daptomycin continues to increase, it is import-
ant for clinicians to recognize and appropriately manage
daptomycin-induced eosinophilic pneumonia. Although
symptoms may resolve upon discontinuation of dapto-
mycin, use of corticosteroid may be beneficial for recov-
ery. Further research is needed to determine the exact
mechanism of daptomycin-induced eosinophilic pneu-
monia and identify the optimal treatment course.
Table 3 Compilation of available data on 35 cases of
daptomycin-induced eosinophilic pneumonia
Sex, n (%)
Male 29 (83)
Female 6 (17)
Age(years), mean ± SD 65.4 ± 15
Daptomycin indication, n (%)
Osteomyelitis/diabetic foot infection 11 (31)
Prosthetic joint infection 9 (26)
Endocarditis 5 (14)
Bacteremia 4 (11)
Abscess 3 (9)
Other 3 (9)
Daptomycin dose (mg/kg/day),
mean ± SD
6.4 ± 1.6
Treatment duration at symptom
onset (weeks), mean ± SD
2.8 ± 1.6
Clinical findings, n (%)
Dyspnea 33 (94)
Fever 20 (57)
Cough 13 (37)
Requiring oxygen 15 (43)
Requiring mechanical ventilation 12 (34)
Infiltrates/opacities of CT/CXR, n (%) 30 (86)
BAL eosinophils %, mean ± SD 32 ± 22.4
Peripheral eosinophilia, n (%) 27 (77)
Lung biopsy consistent with AEP, n (%) 6 (17)
Treatment, n (%)
Daptomycin discontinued only 12 (34)
Daptomycin discontinued plus corticosteroid 23 (66)
AEP acute eosinophilic pneumonia, BAL bronchoalveolar lavage, CT computed
tomography, CXR chest x-ray, SD standard deviation
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